SUPN241220P32000
- 0.00
- 0.000.00%
Supernus Pharmaceuticals Newsroom
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
Analysts Offer Insights on Healthcare Companies: Supernus Pharmaceuticals (SUPN), Editas Medicine (EDIT) and Revvity (RVTY)
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $36
Piper Sandler Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
A Quick Look at Today's Ratings for Supernus Pharmaceuticals(SUPN.US), With a Forecast Between $36 to $43
A Quick Look at Today's Ratings for Supernus Pharmaceuticals(SUPN.US), With a Forecast Between $36 to $43
Analysts Offer Insights on Healthcare Companies: Supernus Pharmaceuticals (SUPN) and Tyra Bioscience (TYRA)
Supernus Pharmaceuticals (SUPN) Gets a Buy From TD Cowen
Piper Sandler Sticks to Their Hold Rating for Supernus Pharmaceuticals (SUPN)
Jefferies Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Cuts Target Price to $40
Jefferies Issues a Buy Rating on Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals Price Target Cut to $36.00/Share From $41.00 by Piper Sandler
Supernus Pharmaceuticals Analyst Ratings
Piper Sandler Downgrades Supernus Pharmaceuticals(SUPN.US) to Hold Rating, Cuts Target Price to $36
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
Strong Buy Rating for Supernus Pharmaceuticals Amidst Robust Revenue Growth and Qelbree's Market Success
Piper Sandler Sticks to Its Buy Rating for Supernus Pharmaceuticals (SUPN)
Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)